Pharma channel feed

Dems slam drug pric­ing strate­gies as 18-month probe comes to an end

5 years ago

A new law could open the door to Cal­i­for­ni­a's own drug pipeline. The state has its sights set on in­sulin first

5 years ago
R&D

FDA is­sues fi­nal rule al­low­ing im­por­ta­tion of drugs from Cana­da — but al­so keeps the pow­er to re­voke it

5 years ago
FDA+

Op-ed: Will phar­ma re­al­ly pay for Trump’s lat­est law­less promise to 33 mil­lion Medicare ben­e­fi­cia­ries? Not like­ly

5 years ago

#ES­MO20: Bris­tol My­ers marks Op­di­vo's sec­ond ad­ju­vant win — eye­ing a stan­dard of care gap

5 years ago
R&D

#ES­MO20: Push­ing in­to front­line, Mer­ck and Bris­tol My­ers duke it out with new slate of GI can­cer da­ta

5 years ago
R&D

#ES­MO20: As­traZeneca aims to spur PRO­found shift in prostate can­cer treat­ment with Lyn­parza OS da­ta

5 years ago
R&D

Trump’s HHS claims ab­solute au­thor­i­ty over the FDA, clear­ing path to a vac­cine EUA

5 years ago

#ES­MO20: As­traZeneca bur­nish­es Tagris­so's ad­ju­vant NSCLC pro­file with 'un­prece­dent­ed' re­duc­tion in brain mets. Can they win over skep­tics?

5 years ago
R&D

Pric­ing deal col­laps­es over Big Phar­ma's re­fusal to is­sue $100 'cash card­s' be­fore the elec­tion — re­port

5 years ago

Seat­tle Ge­net­ic­s' Astel­las-part­nered ADC nails con­fir­ma­to­ry PhI­II in urothe­lial can­cer

5 years ago
R&D

A month af­ter los­ing its lead pro­gram, Uni­ty Biotech­nol­o­gy cuts 30% of staff in re­struc­tur­ing

5 years ago
R&D

Trump ups the stakes with 'grand­dad­dy of them al­l' drug pric­ing ex­ec­u­tive or­der. But he could be run­ning out of time

5 years ago

Gilead CEO Dan O'­Day's $21B M&A deal to buy Im­munomedics gets some harsh re­views

5 years ago
Deals

A year out from FDA ap­proval, Ver­tex looks to ex­pand top-sell­ing CF drug to pe­di­atrics

5 years ago

Phar­ma's bat­tered rep gets a mod­est facelift in the lat­est in­dus­try rat­ings from Gallup — but it's still look­ing pret­ty bad

5 years ago
Bioregnum
Coronavirus

Roche nabs an FDA OK for Gavre­to, trig­ger­ing a heavy­weight bout with ri­vals at Eli Lil­ly

5 years ago
R&D
FDA+

Sam­sung con­struct­ing new $2B 'Su­per Plan­t' rough­ly the size of Amer­i­ca's largest malls

5 years ago
Outsourcing

Amarin los­es patent ap­peal and their brief grip on a car­dio­vas­cu­lar, fish oil em­pire

5 years ago

BIO and a string of CEOs is­sue a call for FDA in­de­pen­dence and against sci­ence-by-press-re­lease

5 years ago
FDA+

Bris­tol My­ers snares an­oth­er ap­proval from the old Cel­gene pipeline, nab­bing an over­looked OK

5 years ago
FDA+

Spurned by the FDA, In­ter­cept brings out the bud­get axe and chops 170 jobs

5 years ago

House Over­sight Com­mit­tee sub­poe­nas Ab­b­Vie over 'woe­ful­ly in­ad­e­quate' doc­u­ment pro­duc­tion in price-goug­ing probe

5 years ago

In the foot­steps of As­traZeneca, No­var­tis com­mits to car­bon-neu­tral sup­ply chain by 2030

5 years ago
First page Previous page 254255256257258259260 Next page Last page
A service from the Financial Times